Scrip
US FDA to reivew extended-release Aricept NDA
25 November 2009
Katie McQue
Please Login to read the full article.
25 November 2009
Katie McQue
The US FDA has accepted for review Pfizer and Eisai's NDA for a higher-dose 23mg once-daily extended-release formulation of their Alzheimer's drug Aricept (donepezil HCl extended release).
The NDA is based in a 1,400 patient head-to-head study comparing the 23mg formulation of Aricept to...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Novo Nordisk's diabetes drug liraglutide stumbles on thyroid cancer concerns
- US panel calls for phased launch of Neuromed/Covidien's long-acting opioid Exalgo
- UK does not favour centralised EU-wide assessment of clinical trials
- Abbott to suspend marketing of obesity drug sibutramine in EU
COMMENT
Other Informa Comment
EVENTS
10 February 2010
London, UK
11 February 2010
London, UK
23 February 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
